Chemometec A/S
CSE:CHEMM
Operating Margin
Chemometec A/S
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DK |
|
Chemometec A/S
CSE:CHEMM
|
9.1B DKK |
46%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
156.6B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
136B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.8B CHF |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
238.5B CNY |
27%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD |
23%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28B USD |
15%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.8B USD |
29%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.5B EUR |
14%
|
Chemometec A/S
Glance View
Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Chemometec A/S's most recent financial statements, the company has Operating Margin of 45.8%.
You don't have any saved screeners yet